{"id":544370,"date":"2021-05-24T13:30:02","date_gmt":"2021-05-24T13:30:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=544370"},"modified":"2021-05-24T13:30:02","modified_gmt":"2021-05-24T13:30:02","slug":"primary-biliary-cholangitis-pbc-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/primary-biliary-cholangitis-pbc-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight_544370.html","title":{"rendered":"Primary Biliary Cholangitis (PBC) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight"},"content":{"rendered":"
\"Primary<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018Primary Biliary Cholangitis \u2013 Market Insights, Epidemiology, and Market Forecast\u20142030\u2019 report deliver an in-depth understanding of the Primary Biliary Cholangitis, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.<\/div>\n

DelveInsight has launched a new report on “Primary Biliary Cholangitis (PBC) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong>”.<\/p>\n

DelveInsight’s “Primary Biliary Cholangitis (PBC) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>” report delivers an in-depth understanding of the Primary Biliary Cholangitis (PBC), historical and forecasted epidemiology as well as the  Primary Biliary Cholangitis (PBC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    According to study, PBC affected individuals are usually in their fifth to seventh decades of life at time of diagnosis, and 90% are women. Annual incidence is estimated at between 1\/1,430,000 and 1\/20,400 inhabitants and prevalence at between 1\/150,000 and 1\/1,063 inhabitants (depending on age and sex).<\/p>\n<\/li>\n

  2. \n

    As per the study, point prevalence of Primary biliary cholangitis was calculated as 27.90 per 100,000 and incidence as 5.31 per 100,000 inhabitants\/year. <\/p>\n<\/li>\n

  3. \n

    As per one study, out of all the studied patients,approximately 7-11% of PBC patients were found to be males.<\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1. Primary Biliary Cholangitis (PBC) market report covers a descriptive overview and comprehensive insight of the Primary Biliary Cholangitis (PBC) epidemiology and Primary Biliary Cholangitis (PBC) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2. The Primary Biliary Cholangitis (PBC) market report provides insights on the current and emerging therapies.<\/p>\n

    3. Primary Biliary Cholangitis (PBC) market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n

    4. The Primary Biliary Cholangitis (PBC) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Primary Biliary Cholangitis (PBC) market.<\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/primary-biliary-cholongitis-market<\/span><\/a>
    <\/a><\/strong><\/p>\n

    Primary Biliary Cholangitis (PBC): Overview<\/strong><\/p>\n

    Primary Biliary Cholangitis (PBC) is a chronic cholestatic disease with a progressive course that may extend over many decades. It is considered an autoimmune disease because of its hallmark serologic signature, antimitochondrial antibody (AMA), and specific bile duct pathology<\/p>\n

    The key players involved in the Primary Biliary Cholangitis (PBC) market:<\/strong><\/p>\n

      \n
    1. \n

      Enanta Pharmaceuticals<\/p>\n<\/li>\n

    2. \n

      Genfit<\/p>\n<\/li>\n

    3. \n

      Chia Tai Tianqing Pharmaceutical<\/p>\n<\/li>\n

    4. \n

      Cara Therapeutics<\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the Primary Biliary Cholangitis (PBC) treatment<\/a> scenario in the upcoming years:-<\/strong><\/p>\n

      Drug covered<\/strong><\/p>\n

        \n
      1. \n

        EDP-305<\/p>\n<\/li>\n

      2. \n

        Elafibranor<\/p>\n<\/li>\n

      3. \n

        TQA3526 <\/p>\n<\/li>\n

      4. \n

        CR845<\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/primary-biliary-cholongitis-market<\/span><\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/p>\n

        2. Executive Summary<\/p>\n

        3. SWOT analysis<\/p>\n

        4. Primary Biliary Cholangitis (PBC) Patient Share (%) Overview at a Glance<\/p>\n

        5. Primary Biliary Cholangitis (PBC) Market Overview at a Glance<\/p>\n

        6. Primary Biliary Cholangitis (PBC) Disease Background and Overview<\/p>\n

        7. Primary Biliary Cholangitis (PBC) Epidemiology and Patient Population<\/p>\n

        8. Country-Specific Patient Population of Primary Biliary Cholangitis (PBC)<\/p>\n

        9. Primary Biliary Cholangitis (PBC) Current Treatment and Medical Practices<\/p>\n

        10. Unmet Needs<\/p>\n

        11. Primary Biliary Cholangitis (PBC) Emerging Therapies<\/p>\n

        12. Primary Biliary Cholangitis (PBC) Market Outlook<\/p>\n

        13. Country-Wise Primary Biliary Cholangitis (PBC) Market Analysis (2017–2030)<\/p>\n

        14. Market Access and Reimbursement of Therapies<\/p>\n

        15. Market drivers<\/p>\n

        16. Market barriers<\/p>\n

        17. Appendix<\/p>\n

        18. Primary Biliary Cholangitis (PBC) Report Methodology<\/p>\n

        19. DelveInsight Capabilities<\/p>\n

        20. Disclaimer<\/p>\n

        21. About DelveInsight<\/p>\n

        Related Reports:<\/strong><\/p>\n

        Primary Biliary Cholangitis – Pipeline Insights, 2021<\/strong><\/p>\n

        “Primary Biliary Cholangitis – Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Primary Biliary Cholangitis market. A detailed picture of the Primary Biliary Cholangitis pipeline landscape is provided, which includes the disease overview and Primary Biliary Cholangitis treatment guidelines.<\/p>\n

        Primary Biliary Cholangitis (PBC) -Epidemiology Forecast to 2030<\/strong><\/p>\n

        DelveInsight’s ‘Primary Biliary Cholangitis- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Primary Biliary Cholangitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight\u2019s \u2018Primary Biliary Cholangitis \u2013 Market Insights, Epidemiology, and Market Forecast\u20142030\u2019 report deliver an in-depth understanding of the Primary Biliary Cholangitis, historical and forecasted epidemiology as well as the market trends in the United States, EU5 … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-544370","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544370","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=544370"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544370\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=544370"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=544370"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=544370"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}